论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Chen DW, Zhang Y, Shi F, Li MH, Zhu H, Kong L, Yu JM
Received 9 June 2015
Accepted for publication 7 August 2015
Published 1 October 2015Volume 2015:8 Pages 2767—2770
DOI http://dx.doi.org/10.2147/OTT.S90145
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Jia Fan
Peer reviewer comments 2
Editor who approved publication: Professor Jianmin Xu
摘要:恶性心包积液(MPCE)是恶性肿瘤的常见并发症,严重影响患者的预后和生活质量。当前,对于恶性心包积液的标准治疗方法是心包内注射化疗药物,但是疗效并不十分显著,而且会引起一些较为严重的化疗毒副反应。我们报道了一例用贝伐单抗治疗肺癌引起的心包积液的病例,取得了显著的疗效。我们认为,用贝伐单抗治疗恶性心包积液有很大的临床价值。
Keywords: bevacizumab, lung cancer, malignant pericardial effusion